Cassava Sciences, Inc.
Symbol: SAVA (NASDAQ)
2.14
▼ (-1.88%) -0.041
Company Description:
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Key Stats
- Today's Open: $2.15
- Today's High: $2.165
- Today's Low: $2.1
- Today's Volume: 528.27K
- Yesterday Close: $2.18
- Yesterday High: $2.2
- Yesterday Low: $2.13
- Yesterday Volume: 405.00K
- Last Min Volume: 0
- Last Min High: $2.139
- Last Min Low: $2.136
- Last Min VWAP: $0
Company Profile
- Name: Cassava Sciences, Inc.
- Website: https://www.cassavasciences.com
- Listed Date: 2000-07-14
- Location: AUSTIN, TX
- Market Status: Active
- CIK Number: 0001069530
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $103.38M
- Round Lot: 100
- Outstanding Shares: 48.31M
- Asset Type: CS
RECENT FILINGS FOR SAVA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-08 | 8-K | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | 8-K | View |
| 2025-08-04 | 8-K | View |
| 2025-07-29 | SCHEDULE 13G/A | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-07-16 | 4 | View |
| 2025-06-30 | 8-K | View |
| 2025-05-27 | 4 | View |
| 2025-05-27 | 4 | View |
| 2025-05-27 | 4 | View |
| 2025-05-27 | 4 | View |
| 2025-05-27 | 4 | View |
| 2025-05-27 | 8-K | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-08 | 8-K | View |
| 2025-04-21 | 4 | View |
| 2025-04-21 | 4 | View |
| 2025-04-21 | 4 | View |
| 2025-04-21 | 4 | View |
Latest News on SAVA